Corporate Overview

Viral Genetics, Inc. is a biotechnology company researching treatments and methods of detection for HIV/AIDS, Lyme Disease, staph and strep, cancer and certain other autoimmune and infectious diseases. Two approaches based on patent rights licensed from the University of Colorado and University of Vermont form the basis of our research: Targeted Peptides Therapies (TPT) and Metabolic Disruption Technology (MDT). TPTs are custom-designed protein fragment that work to modify certain immune system reactions that we believe cause or worsen some diseases. The TPT compounds we are studying represent in some sense the second generation of our earlier TNP therapy. MDT encompasses a way to change how some types of cells use fat and sugar for energy. By manipulating this metabolic process, we believe we can cause some harmful cells – including drug-resistant cancer cells – to die. The same MDT approach has also recently been discovered to have potential in encouraging the production of biofuels from algae.

Our management team and advisors include two Nobel Laureates, leading researchers, business and intellectual property veterans and drug development experts.

Recent Headlines

Viral Genetics Inc. Issues 2011 Year in Review and 2012 Outlook
Click here for full story

VG Energy Highlighted in Branson's "Carbon War Room" Jet Fuel Initiative
Click here for full story

Cheap Valuations in Viral Genetics and AEterna Zentaris Embraced by Investors
Click here for full story

Patent Licensed Exclusively to Viral Genetics to be Granted for DCA as Cancer Treatment
Click here for full story

VG Energy Appoints Two Veteran Businessmen with History of Successful Early Stage Investing to Board of Directors
Click here for full story

New to Viral Genetics?

View our History and learn more About Us.

Stock Quote

Click here for a recent stock quote: VRAL.PK